Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
NovoCure Limited (NASDAQ: NVCR)
NVCR Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
6.90%
Analyst Rating:
BUY
Analyst Forecast (1yr):
48%
NVCR Stock Analysis
NVCR
PE Ratio:
NVCR
PEG Ratio:
Not Available
NVCR
Forward EPS Growth (12 month):
0.00%
NVCR
PS Ratio:
2.8
NVCR
PSG Ratio:
0.3
NVCR
Forward Revenue Growth (12 month):
10.40%
NVCR Articles
No data was found